UroGen Pharma Stock Forecast

Stock Price Forecast

The 8 analysts that cover UroGen Pharma stock have a consensus rating of "Strong Buy" and an average price target of $29, which forecasts a 106.55% increase in the stock price over the next year. The lowest target is $3 and the highest is $50.

Price Target: $29 (+106.55%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$3.00	$29	$31	$50
Change	-78.63%	+106.55%	+120.80%	+256.13%

Analyst Ratings

The average analyst rating for UroGen Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	5	5	5	5	5	5
Buy	1	1	1	1	2	2
Hold	0	0	1	2	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	7	8	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $50	Strong Buy	Reiterates	$50	+256.13%	Jul 8, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $25	Strong Buy	Maintains	$25	+78.06%	Jul 7, 2025
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Hold → Strong Buy Upgrades $50	Hold → Strong Buy	Upgrades	$50	+256.13%	Jun 16, 2025
Leland Gershell Oppenheimer	Oppenheimer	Buy Maintains $10 → $31	Buy	Maintains	$10 → $31	+120.80%	Jun 13, 2025
George Farmer Scotiabank	Scotiabank	Buy Maintains $23 → $47	Buy	Maintains	$23 → $47	+234.76%	Jun 13, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

126.38M

from 90.40M

39.80%

from 90.40M

Revenue Next Year

264.06M

from 126.38M

108.94%

from 126.38M

EPS This Year

-2.97

from -2.96

EPS Next Year

-1.32

from -2.97

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	11.80M	48.04M	64.36M	82.71M	90.40M	126.38M	264.06M	404.84M
Revenue Growth	65,450.00%	307.17%	33.96%	28.52%	9.29%	39.80%	108.94%	53.31%
EPS	-5.90	-4.96	-4.81	-3.55	-2.96	-2.97	-1.32	0.70
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	20.12
No. Analysts	-	-	-	-	-	10	10	9

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	143.3M	411.1M	741.7M
Avg	126.4M	264.1M	404.8M
Low	109.9M	219.9M	298.7M

Revenue Growth

Revenue Growth	2025	2026	2027
High	58.6%	225.2%	180.9%
Avg	39.8%	108.9%	53.3%
Low	21.6%	74.0%	13.1%

EPS Forecast

EPS	2025	2026	2027
High	-2.35	2.14	4.24
Avg	-2.97	-1.32	0.70
Low	-3.40	-3.03	-1.39

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.